Fundamentals · LLY
Peer Comparison for LLY
AI-generated plain-English read of peer comparison for LLY. Updated daily.
Rich premium vs peers — in-line growth
moderateLLY trades at 1.66x the sector median, but its superior fundamentals explain most of the premium — this is pricing quality, not irrational exuberance.
What will probably happen
- Premium names with justified multiples tend to hold their valuation through earnings cycles — the risk is an execution miss, not fundamental deterioration.
- Watch estimate revisions closely: any guidance cut on growth or margin compresses a premium multiple faster than an in-line stock.
What to do
- If you HOLD this stock
- Premium is justified by best-in-class fundamentals. The risk is execution disappointment — any growth miss will compress the multiple sharply. Hold but watch quarter-end estimate revisions tightly.
- If you're EVALUATING this stock
- Quality at a price; reasonable to enter on macro-driven pullbacks rather than chasing peak multiples.
- If you trade OPTIONS
- Sell call premium against shares (covered calls); IV is typically rich on premium-multiple names. Collect premium while the multiple consolidates.
9 peers and 2 valuation metric(s) — sufficient but not robust. Treat directional buckets as indicative rather than definitive.
Technical details
Technical analysis
- Sector
- Pharmaceuticals
- Peer count
- 9
- Target P/E
- 32.6x
- Outlier flag
- Structural
- Growth ranking
- In Line Growth
- Peer median P/E
- 19.7x
- Profitability rank
- Best In Class
- Relative valuation
- Rich Premium
- Relative multiple (target / peer median)
- 1.66x
Key levels
| Level | Value |
|---|---|
| n peers | 9 |
| target pe | 32.601 |
| peer median pe | 19.655 |
| valuation ratio | 1.659 |
Caveats
- Peer comparisons are a single-snapshot read. Multi-quarter trends often matter more than current-quarter relative levels.